TAGI Pharma Announces Exclusive Marketing Rights Agreement for Codeine Sulfate Oral Solution CII, 30MG/5ML

SOUTH BELOIT, Ill., April 10, 2012 (GLOBE NEWSWIRE) -- TAGI Pharma, Inc., a subsidiary of Precision Dose, Inc., announced today the signing of an exclusive marketing rights agreement to market and sell the approved NDA product, Codeine Sulfate Oral Solution CII, 30mg/5mL in the United States and its territories, possessions and protectorates.

MORE ON THIS TOPIC